• Vertex Offers England a Portfolio Approach for Access to Orkambi and Future CF Therapies
  • Vertex Begins First Phase 3 Trial Testing CF Triple Combo Therapy VX-659, Tezacaftor and Kalydeco
  • Remote Healthcare Monitoring Company PMD Creates CF and PF Patient Advisory Boards
  • A Lifetime of Anger: From Darth Bradious to the Incredible Brulk
  • Patient Advocacy Groups Worldwide Plan Events to Mark Rare Disease Day, Feb. 28
  • Santhera to Develop, Market Polyphor Experimental CF Therapy
  • Arch Biopartners Enrolling Volunteers in Phase 1 Trial of AB569, Therapy Candidate for Drug-resistant Bacterial Lung Infections
  • Trial Investigating AzurRx’s Replacement Therapy for EPI Completes 75% Enrollment
  • Australian Scientist Gets $1 Million to See if Probiotics Can Help Children with CF
  • Let’s Talk About Marijuana
  • FDA Approves Symdeko, Vertex’s Combo Therapy for Patients with Certain Mutations in CFTR Gene
  • 2 CF Case Reports Show Successful Use of GM-CSF for Treating Nontuberculous Mycobacteria